...
首页> 外文期刊>Journal of infectious disease pharmacotherapy >Role of a Clinical Pharmacist on Drotrecogin Alfa (Activated) Outcomes in a Large Community Teaching Hospital
【24h】

Role of a Clinical Pharmacist on Drotrecogin Alfa (Activated) Outcomes in a Large Community Teaching Hospital

机译:在大型社区教学医院中临床药师在Drotrecogin Alfa(活化)结果中的作用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Drotrecogin alfa (activated), a recombinant form of Human Activated Protein C (APC), is indicated for the treatment of adults with severe sepsis and appears to have the greatest mortality benefit in those patients with a high-risk of death (APACHE II >= 25). Due to this observation and its high acquisition cost, a multidisciplinary team was assembled to develop a strict protocol for the use of APC at our institution. This protocol required a clinical pharmacist to evaluate all candidates for appropriateness before receiving APC therapy. Herein, we report the role of a clinical pharmacist in determining appropriate candidates to receive APC and the subsequent effects on clinical and economic outcomes. Patients receiving APC consults between 01/2002 and 01/2003 were divided into two groups, those who met protocol criteria (Group I) and those who did not (Group II). Data were collected for patient demographics, APACHE II score, type of ICU, site of infection, 28-day mortality, and bleeding incidence. Cost analysis was done using the Average Wholesale Price (AWP) of APC and the national average hourly salary for a full time clinical pharmacist. Costs saved were estimated by the cost of APC that would have been administered to patients who did not meet criteria and were alive at 28-days. Thirty-four patients were consulted (Group I: 20, Group II: 14). There was no statistically significant difference between Group I and II regarding demographics, type of ICU, site of infection, and bleeding incidence. APACHE II scores were high and similar for both groups (Group I: 31 + 6; Group II: 29 ± 6, p = 0.394). Despite not meeting protocol criteria as determined by the clinical pharmacist, 8 patients in Group II received APC therapy. Twenty-eight day mortality was lower in patients determined to be appropriate candidates for APC therapy by the clinical pharmacist (Group 1:30% vs. Group II: 64%, p = 0.08). Cost analysis demonstrated that a total of
机译:Drotrecogin alfa(活化的),一种人类活化蛋白C(APC)的重组形式,适用于患有严重脓毒症的成年人,在那些具有高死亡风险的患者中似乎具有最大的死亡获益(APACHE II> = 25)。由于这种观察及其高昂的购置成本,组建了一个多学科小组,以制定严格的协议,以便在我们机构使用APC。该方案要求临床药剂师在接受APC治疗之前评估所有候选药物的适用性。在此,我们报告了临床药剂师在确定合适的候选人来接受APC以及随后对临床和经济结果的影响方面的作用。在01/2002年至01/2003年接受APC咨询的患者分为两组,符合方案标准的患者(第一组)和不符合方案标准的患者(第二组)。收集有关患者人口统计学,APACHE II评分,ICU类型,感染部位,28天死亡率和出血发生率的数据。成本分析是使用APC的平均批发价格(AWP)和全职临床药剂师的全国平均小时工资进行的。节省的成本是根据APC的成本来估算的,该成本将用于不符合标准且在28天还活着的患者。咨询了34名患者(第一组:20名,第二组:14名)。在人口统计学,ICU类型,感染部位和出血发生率方面,I组和II组之间没有统计学上的显着差异。两组的APACHE II得分均很高且相似(第一组:31 + 6;第二组:29±6,p = 0.394)。尽管不符合临床药剂师确定的方案标准,但II组中有8例患者接受了APC治疗。经临床药剂师确定为适合APC治疗的患者的第二十八天死亡率较低(组1:30%,组II:64%,p = 0.08)。成本分析表明,总计

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号